Company intelligence / Profile preview
SGN Nanopharma
Tampa, Florida, United Statessgnnanopharma.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Clinical
01
Overview
SGN Nanopharma's MNP Cyclosporine demonstrated statistically superior efficacy compared to the current standard of care for dry eye disease in a head-to-head clinical study, with greater effects observed within four weeks and a lower incidence of side effects such as corneal irritation[4].
- Therapeutic areas
- OphthalmologyOther
- Modalities
- NanoparticleSmall moleculeCombination therapyBiologic
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Eyenovia
Beyond the preview
Go deeper on SGN Nanopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGN Nanopharma.